After the applause: New efficacy expectations in urothelial cancer after Padcev-Keytruda data reveal

Urothe­lial can­cer on­col­o­gist Matthew Gal­sky has trou­ble re­mem­ber­ing the last time there was a stand­ing ova­tion for clin­i­cal tri­al da­ta at a med­ical con­fer­ence. But he wasn’t sur­prised that con­fir­ma­to­ry da­ta from a Phase III tri­al study­ing Seagen and Astel­las’ Pad­cev plus Mer­ck’s Keytru­da in first-line blad­der can­cer was met with one just over a week ago at ES­MO.

“Since the de­vel­op­ment of plat­inum-based chemother­a­py around 30-plus years ago, there have been no im­prove­ments in sur­vival in pa­tients with metasta­t­ic blad­der can­cer or urothe­lial can­cer,” said Gal­sky, a pro­fes­sor at the Ic­ahn School of Med­i­cine at Mount Sinai.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.